Artegraft Versus Propaten Dialysis Grafts
| Status: | Terminated |
|---|---|
| Conditions: | Renal Impairment / Chronic Kidney Disease |
| Therapuetic Areas: | Nephrology / Urology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 7/8/2018 |
| Start Date: | April 2014 |
| End Date: | November 2014 |
A Prospective, Randomized Study of the Artegraft vs Propaten Vascular Grafts for Renal Failure Patients Requiring Dialysis Access
Compare Artegraft and Propaten grafts for use in dialysis access to see if one performs
better than the other. How long each one lasts until a complication arises or until the graft
is no longer used will be compared.
The study hypothesis is that the Artegraft, being an actual blood vessel, will work better
than the manufactured Propaten graft.
better than the other. How long each one lasts until a complication arises or until the graft
is no longer used will be compared.
The study hypothesis is that the Artegraft, being an actual blood vessel, will work better
than the manufactured Propaten graft.
Approximately 50 eligible patients with End Stage Renal Disease (ESRD) requiring hemodialysis
will be randomized to receive one of these two grafts as part of their standard care.
Patients will be assessed at 2-3 weeks post-operatively and again at 6 and 12 months for flow
characteristics, dialysis adequacy and graft associated complications such as stenosis,
infection and thrombosis. Data on urea reduction ratio (URR), kinetic modeling (Kt/V), and
access flow (QB) will be collected at 3, 6, 9 and 12 months via phone call to the
hemodialysis center in order to evaluate patency and function.
Access complications (stenosis, thrombosis, infection) will be treated per our standard
protocol. These data will be recorded and then primary, assisted primary and secondary
patency rates will be calculated and the graft arms compared using life table analysis.
will be randomized to receive one of these two grafts as part of their standard care.
Patients will be assessed at 2-3 weeks post-operatively and again at 6 and 12 months for flow
characteristics, dialysis adequacy and graft associated complications such as stenosis,
infection and thrombosis. Data on urea reduction ratio (URR), kinetic modeling (Kt/V), and
access flow (QB) will be collected at 3, 6, 9 and 12 months via phone call to the
hemodialysis center in order to evaluate patency and function.
Access complications (stenosis, thrombosis, infection) will be treated per our standard
protocol. These data will be recorded and then primary, assisted primary and secondary
patency rates will be calculated and the graft arms compared using life table analysis.
Inclusion Criteria:
- > 18 years of age
- Candidate for hemodialysis
- Not a candidate for native AV fistula
- In need of a new AV graft in the upper arm location
- Artery and vein > 3mm.
- Medically stable and have a life expectancy of ≥ 12 months
- The patient or legal guardian understands the study and is willing to comply with the
requirements.
Exclusion Criteria:
- < 18 years of age
- Current history or within 6 months of IV drug abuse
- Chronic hypotension (<100 mm systolic pressure) not responsive to treatment
- Pregnant or lactating
- Known hypercoagulable state
- Requires only a revision of an existing graft
- Receiving artery or vein is less than 3 mm in diameter at the time of implantation
- Known axillary/subclavian occlusion or stenosis that has not been treated
- Known or suspected systemic infection
- Heparin sensitivity (known HIT)
- Enrolled in another investigational study.
- Subject has more than 1 graft in target limb.
We found this trial at
1
site
Click here to add this to my saved trials
